Brief: Synact Pharma Carries Out Directed Share Issue Of SEK 80 Mln

SynAct Pharma AB

12/12/2022 06:35

Dec 12 (Reuters) - SynAct Pharma AB  SYNACT.ST :
    * SYNACT PHARMA CARRIES OUT A DIRECTED SHARE ISSUE OF SEK 80
MILLION IN CONNECTION WITH THE ACQUISITION OF TXP PHARMA
    * IN CONJUNCTION WITH ACQUISITION OF TXP PHARMA BOD DECIDED
TO
CARRY OUT DIRECTED SHARE ISSUE OF 1,277,954 SHARES AT
SUBSCRIPTION PRICE OF SEK 62.60 PER SHARE
    * DIRECTED SHARE ISSUE IS ISSUED TO COMPANIES CONTROLLED BY
THOMAS
VON KOCH AND CHRISTIAN KINCH
    * DIRECTED SHARE ISSUE WILL PROVIDE COMPANY WITH SEK 80
MILLION
BEFORE TRANSACTION COSTS RELATING TO DIRECTED SHARE ISSUE
    * INVESTMENT FROM THOMAS VON KOCH AND CHRISTIAN KINCH AND
COMPLETION OF DIRECTED SHARE ISSUE IS NOT CONDITIONAL ON
COMPLETION OF ACQUISITION OF TXP
    * IN DIRECTED SHARE ISSUE, THOMAS VON KOCH (VIA A COMPANY)
INVESTS
SEK 70 MILLION AND A COMPANY JOINTLY CONTROLLED BY THOMAS VON
KOCH AND CHRISTIAN KINCH INVESTS SEK 10 MILLION
    * INTENDS TO USE ISSUE PROCEEDS TO FINANCE (I) DEVELOPMENT
OF
ASSETS ACQUIRED FROM TXP, (II) FURTHER STRENGTHENING DEVELOPMENT
ACTIVITIES RELATED TO AP1189
    * ALSO INTENDS TO USE ISSUE PROCEEDS TO FINANCE (III)
GENERAL
CORPORATE PURPOSES, EXTENDING RUNWAY THROUGH TO MID-2024
    * DIRECTED SHARE ISSUE ENTAILS DILUTION OF ABOUT 4.3% OF
TOTAL
NUMBER OF SHARES, VOTES FOR EXISTING SHAREHOLDERS, BASED ON
TOTAL NUMBER OF SHARES IN CO AFTER DIRECTED SHARE ISSUE

Source text for Eikon:  ID:nMFN33JyYy 
Further company coverage:  SYNACT.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))